Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 +0.38%95 PB Ratio is 4.45 as of Jul. 16, 2026, which is 42% below its 10-year median of 7.63. GuruFocus rates BSP:RADL3 with a GF Score™ of 95/100 and a GF Value™ of R$30.01 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 610 Healthcare Providers & Services companies, Raia Drogasil ranks worse than 76.72% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), Raia Drogasil's share price is R$18.67. Raia Drogasil's Book Value per Share for the quarter that ended in Mar. 2026 was R$4.20. Hence, Raia Drogasil's PB Ratio of today is 4.45.
The historical rank and industry rank for Raia Drogasil's PB Ratio or its related term are showing as below:
BSP:RADL3'
s PB Ratio Range Over the Past 10 Years
Min: 3.47 Med: 7.63 Max: 10.68
Current: 4.45
During the past 13 years, Raia Drogasil's highest PB Ratio was 10.68. The lowest was 3.47. And the median was 7.63.
BSP:RADL3's PB Ratio is ranked worse than 76.72% of 610
companies
in the Healthcare Providers & Services industry
Industry Median: 2.01
vs BSP:RADL3: 4.45
During the past 12 months, Raia Drogasil's average Book Value Per Share Growth Rate was 13.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Raia Drogasil was 87.70% per year. The lowest was -15.80% per year. And the median was 10.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Raia Drogasil PB Ratio Related Terms
Raia Drogasil PB Ratio Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's PB Ratio distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Raia Drogasil's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Raia Drogasil (BSP:RADL3) has a PB Ratio of 4.45 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Raia Drogasil and its competitors. This is 42% below median its historical median of 7.63. Over the past decade, Raia Drogasil's PB Ratio has ranged from 3.47 to 10.68. According to the industry distribution chart, Raia Drogasil ranks #468 out of 610 companies in the Healthcare Providers & Services industry, placing it in the top 76.7%.
Is Raia Drogasil's PB Ratio too high?
Raia Drogasil's current PB Ratio of 4.45 is 42% below median its 10-year median of 7.63. Over the past 10 years, this metric has ranged from a low of 3.47 to a high of 10.68. The Healthcare Providers & Services industry median PB Ratio is 2.01. Raia Drogasil's value of 4.45 is 121.4% above this industry median. Based on the distribution chart, Raia Drogasil ranks #468 out of 610 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Raia Drogasil has a GF Score™ of 95/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's PB Ratio compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #468 out of 610 companies for PB Ratio. This places Raia Drogasil in the lower half of its industry. The industry median PB Ratio is 2.01. Raia Drogasil's value of 4.45 is 121.4% above this benchmark. Historically, Raia Drogasil's own PB Ratio has ranged from 3.47 to 10.68 over the past decade. While the company's 10-year median is 7.63 vs. the industry median of 2.01, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 2.01, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current PB Ratio of 4.45 is 121.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Raia Drogasil and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current PB Ratio is 4.45, which is 42% below median its own 10-year median of 7.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$30.01, compared to a current price of R$18.67 — trading 37.8% below its estimated fair value. The current PB Ratio is 4.45, which is 42% below median its 10-year median of 7.63 and 121.4% above the Healthcare Providers & Services industry median of 2.01. Raia Drogasil's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current PB Ratio is 4.45 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$18.67 is trading 37.8% below its estimated GF Value™ of R$30.01.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
PB Ratio: 4.45 (42% below median its 10-year median of 7.63)
GF Value™: R$30.01 vs. price of R$18.67 (37.8% below fair value)
Industry Position: 121.4% above the Healthcare Providers & Services median (#468 of 610)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
95GF Score
Get the complete analysis for BSP:RADL3
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
